Image

Cardiovascular Disease Cohort

Recruiting
18 - 80 years of age
Both
Phase N/A

Powered by AI

Overview

The Cardiovascular Disease Cohort study is a prospective cohort study among cardiovascular disease patients enrolled in the Affiliated Hospital of Hangzhou Normal University. The primary aim of this study is to explore the brain mechanism of cognitive decline in cardiovascular disease patients using RS-FMRI and multi-omics techniques (including microbiome and metabolomics). Another aim of this study is to develop diagnosis and treatment strategies combining cardiovascular disease and cognitive function.

Eligibility

  1. Atrial fibrillation patients

Inclusion Criteria:

  • Age: 45-80 years old;
  • Consistent with the diagnosis of atrial fibrillation: standard 12-lead ECG recording or ≥30s single-lead ECG recording or 24-hour dynamic electrocardiogram, no obvious repeated P wave, irregular RR interval (when it does not damage atrioventricular conduction) can be diagnosed as clinical atrial fibrillation;
  • Anticoagulant therapy was selected according to cha2DS2-VASC score and HASBLED score;
  • Voluntarily participate in the study and sign the informed consent.

Exclusion Criteria:

  • Valvular atrial fibrillation, atrial fibrillation caused by hyperthyroidism;
  • Severe liver and kidney failure;
  • Malignant tumor;
  • Diseases of the blood system;
  • History of major surgical trauma within six months. 2. Left ventricular hypertrophy patients

Inclusion Criteria:

  • Age: 45-80 years old;
  • ECG diagnosis of left ventricular hypertrophy: increased QRS group voltage: CHEST lead Rv5 or Rv6>2.5mV; Rv5+Sv1>4.0mV (male) or >3.5mV (female) Or in the limb lead, R1>11.5 mV; RaVL > 1.2 mV; RaVF > 2.0 mV; RI + SIII > 2.5 mV;
  • Sign informed consent to participate in the study voluntarily.

Exclusion Criteria:

  • Left ventricular hypertrophy caused by valvular heart disease and hyperthyroidism;
  • Severe liver and kidney failure;
  • Malignant tumor;
  • Diseases of the blood system;
  • History of major surgical trauma within six months. 3. Pulmonary hypertension patients

Inclusion Criteria:

  • Age: 18-80 years;
  • Consistent with the diagnosis of pulmonary hypertension: at sea level and resting state, average pulmonary arterial pressure (mPAP) ≥25 mmHg (1mmHg=0.133kPa) measured by right heart catheter, or pulmonary arterial pressure ≥35 mmHg estimated by tricuspid regurgitation velocity indicated by cardiac ultrasound;
  • Sign informed consent to participate in the study voluntarily.

Exclusion Criteria:

  • Patients with other serious cardiovascular and cerebrovascular diseases;
  • Severe liver and kidney failure;
  • Malignant tumor;
  • Diseases of the blood system;
  • History of major surgical trauma within six months. 4. Patients with coronary atherosclerotic heart disease

Inclusion Criteria:

  • Age: 45-80 years old;
  • In line with the diagnosis of coronary heart disease: coronary artery stenosis indicated by CORONARY CTA or angiography, with a severity of more than 50%, accompanied by symptoms of chest distress and chest pain;
  • Sign informed consent to participate in the study voluntarily.

Exclusion Criteria:

  • Severe valvular heart disease, hyperthyroidism, etc;
  • Severe liver and kidney failure;
  • Malignant tumor;
  • Diseases of the blood system;
  • History of major surgical trauma within six months. 5. Heart failure with retained ejection fraction patients

Inclusion Criteria:

  • Age: 45-80 years;
  • Patients with HFpEF diagnosis had clinical symptoms or signs of cardiac insufficiency, cardiac echocardiography suggested left ventricular eject fraction (LVEF≥50%), increased natriuretic peptide, and met at least one of the following criteria: a. Left ventricular hypertrophy and/or left atrium enlargement; B. Abnormal diastolic function of the heart.
  • It is necessary to rule out that the patient's symptoms are not caused by heart disease; ④ Voluntarily participate in the study and sign the informed consent.

Exclusion Criteria:

  • Severe cervical and cerebrovascular events, such as severe carotid artery plaque or stenosis (stenosis rate greater than 50%), cerebral ischemic stroke, etc;
  • Severe liver and kidney failure;
  • Malignant tumor;
  • Diseases of the blood system;
  • History of major surgical trauma within six months.

Study details

Cognitive Decline, Cardiovascular Diseases

NCT05309824

Westlake University

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.